BioNTech’s Governance Overhaul and $650M R&D Burn Precede the Ultimate Test: Pumitamig vs. Keytruda

Shareholders of the Mainz-based biotech gave management a resounding endorsement this month, but the market is waiting for a different kind of verdict. At a virtual annual general meeting on 15 May 2026, 92% of voting capital approved a board expansion from six to eight members and authorized a capital increase of up to 50% of existing share capital. The moves are designed to fortify the company’s oncology push – a transition that is already costing hundreds of millions of euros per quarter against dwindling vaccine revenue.

The two new supervisory board members bring precisely the expertise BioNTech needs as it shifts from pandemic-era dominance to a full-blown cancer drug developer. Prof. Iris Löw-Friedrich, a clinician with experience in clinical development, international markets and commercialization, also teaches internal medicine at Goethe University Frankfurt. Susanne Schaffert, who sits on Merck KGaA’s board, adds depth in oncology, sales and product launches. Their appointments fill gaps that will become critical as the company tries to turn a pipeline of more than 20 active late-stage trials into marketed medicines.

Alongside the boardroom changes, shareholders gave the go?ahead for a capital increase of up to half the current share capital. With roughly $20 billion in cash on hand, the authorization looks less like an emergency measure and more like strategic preparation for potential acquisitions or partnerships. The company also announced a billion?euro buyback programme for American Depositary Shares over the next twelve months, a sign that management sees value in its own stock even as the market remains sceptical.

Should investors sell immediately? Or is it worth buying BioNTech?

The financial picture is sobering. In the first quarter of 2026, BioNTech posted revenue of €118.1 million, a fraction of the sums it earned during the vaccine boom, while its R&D expenditure alone hit $650 million. The net loss stood at €531.9 million. For the full year, the company maintains its revenue guidance of €2.0 billion to €2.3 billion – a target that depends heavily on its remaining vaccine franchise and, eventually, on the commercial success of its oncology candidates.

At the centre of the near-term narrative lies the ASCO annual meeting, running from 29 May to 2 June. BioNTech will present phase 2 data from the ROSETTA Lung?02 study, in which its bispecific antibody pumitamig is taking on pembrolizumab (Keytruda), the current standard of care in first-line immunotherapy for lung cancer. The outcome will either validate the company’s expensive pivot or widen the gap between its aspirational governance changes and the clinical proof needed to back them up.

The stock’s trajectory reflects the uncertainty. BioNTech shares closed at €76.95 on Friday, shedding 2.84% over the week and 11.55% over the month. Year?to?date, the equity is down 6.73%, with the 52?week high of €101.90 still far out of reach and the low of €72.50 uncomfortably close. Analyst price targets range from $94 to $171 – a spread that underscores how much the valuation hinges on upcoming data rather than on the balance sheet or the boardroom.

Investors have granted BioNTech the latitude and capital it needs to build an oncology powerhouse. Whether those resources translate into a durable pipeline will be determined over the next six days in Chicago. The ASCO readout is the first major external anchor for a strategy that so far has been funded largely by faith and a war chest built on the back of Comirnaty.

Ad

BioNTech Stock: New Analysis - 18 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH’S | boerse | 69363568 |